From PhillyVoice · · 1m 20s
Trump admin funds ibogaine PTSD trials
Trump administration allocates $4.9 million for ibogaine clinical trials to treat veteran PTSD.
In brief
Trump administration allocates $4.9 million for ibogaine clinical trials to treat veteran PTSD. Trump administration funds $4.9 million to research ibogaine for PTSD treatment in veterans. Originally reported by PhillyVoice.
Funding announcement
Trump administration announces $4.9 million for ibogaine clinical trials targeting veteran PTSD.
Ibogaine background
Ibogaine, a psychoactive plant from Central and West Africa, is illegal in the U.S. and classified with LSD.
2024 study results
Small 2024 study showed ibogaine provides fast-acting relief for veteran PTSD but also linked to heart risks.
Rogan influence
Podcaster Joe Rogan reportedly urged Trump administration to fund ibogaine research through direct communication.
Health secretary statement
Health and Human Services Secretary Robert F. Kennedy Jr. said veterans described ibogaine as life-changing.
Heart risks
Ibogaine has been linked to severe heart effects and deaths according to Rutgers Brain Health Institute.
Previous support
Trump administration previously signed executive order to fast-track FDA approval for psychedelic mental health treatments.
Treatment context
PTSD affects 7% of veterans and 6% of general population, with higher rates among female veterans.
Current status
Ibogaine research remains limited due to U.S. classification as illegal psychedelic substance.
Next steps
Administration aims to balance ibogaine's potential benefits with safety concerns for veterans.
The headline
Trump administration funds $4.9 million to research ibogaine for PTSD treatment in veterans.
